- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04433260
COVID19 and Physical and Emotional Wellbeing of HCP (CoPE-HCP)
Immediate and Mid-term Implications of the Covid-19 Pandemic on the Physical, Behavioural and Mental Health of Healthcare Workers: A Cohort Study of Doctor, Nurses and Other Health Care Workers
The current COVID-19 pandemic has affected more than 3 million people worldwide across more than 200 countries.
In the United Kingdom alone, at the end of April, there were almost 160,000 confirmed cases with more than 20,000 deaths. This has undoubtedly had significant physical and economical impact on the public.
Healthcare workers are at high risk of developing life-threatening infectious diseases with increased exposure to patients' blood and bodily fluids. As such, health care workers arguably experience heightened anxiety and are predisposed to greater negative psycho-social impact from the current COVID-19 pandemic.
The aim of this study is to evaluate the physical and psychological impact of COVID-19 on healthcare workers. This will be performed in two phases.
In phase 1, investigators will collect information to evaluate the current psychiatric symptom profile (in particular, screening for anxiety or depression related symptoms), alcohol use, sleep-related complaints and overall well-being among healthcare workers who participate in this survey (with a focus on junior doctors). In addition the association of these mental health and behavioural parameters with the prevalence of stressful occasions, such as long-hours, unpredictability of work / redeployment, availability of personal protection equipment and concerns regarding family/relationship and self will be assessed.
In phase 2, investigators will then reassess for the development or progression of psychiatric symptoms, use of alcohol and other substances, behavioural or interpersonal relationship changes as well as physical well-being at 6 weeks and 4- months. Physical well-being is assessed through the presence of suspected or confirmed COVID-19 infection and absence from work. Specifically, investigators will study the impact of variable provision of personal protection equipment (supply and training), extended working hours, and concern for well-being of family members, on work morale and anxiety levels.
Another aim is also study the longer term mental health consequences of the current pandemic on health care workers.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, EC1M 6BQ
- Ajay K Gupta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 (n = minimum 800)
Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19 (minimum n= 125) (internal control)
Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected (minimum n=125) (population control)
Description
Inclusion Criteria:
- Aged >=18
- Electronic consent
- Either:
a - healthcare workers in contact with patients with confirmed or suspected COVID-19 b - Healthcare staff not having direct patient contact c - Non-healthcare academic staff with no direct patient contact
Exclusion Criteria:
- Age<18
- Individuals not belonging to the 3 cohorts of interest listed in the inclusion criteria.
- Those who are not able to understand written English will be excluded, indeed by the design and methodology of the study, as the study invite and all other information provided is in English.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cases
Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19
|
The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders.
A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Other Names:
Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey.
This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Participants will need to give their consent to participate to the survey after reading PIS
|
Internal Control
Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19.
|
The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders.
A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Other Names:
Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey.
This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Participants will need to give their consent to participate to the survey after reading PIS
|
Population Control
Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected.
|
The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders.
A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Other Names:
Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey.
This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Participants will need to give their consent to participate to the survey after reading PIS
|
Follow-up cases
Doctors, nurses and other healthcare workers ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 consenting to receive follow-up surveys (n ~ 400)
|
The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders.
A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Other Names:
Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey.
This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Participants will need to give their consent to participate to the survey after reading PIS
|
Follow-up controls
Healthcare Administrative staff who are working in the hospital, not at risk of work-related exposure to patients potentially infected with COVID-19 (n~80)
|
The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders.
A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Other Names:
Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey.
This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Participants will need to give their consent to participate to the survey after reading PIS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of anxiety at baseline
Time Frame: baseline
|
Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. |
baseline
|
Presence of depression at baseline
Time Frame: baseline
|
Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression |
baseline
|
Proportion of those who report a combined outcome of presence of anxiety or depression at the baseline as determined by screening questionnaires used.
Time Frame: baseline
|
Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Higher score corresponding to more severe degree of anxiety. |
baseline
|
Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study
Time Frame: 4 months
|
Anxiety will be investigated by 7-item Generalised Anxiety Disorder and depression will be investigated by 9-item patient health questionnaire. Presence of either one of those or both will be taken as the combined outcome. For anxiety, 7-item Generalized anxiety disorder score (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. For depression, the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression |
4 months
|
Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study
Time Frame: 4 months
|
Self reported, assessed based on the questions regarding the presence of symptoms with presence of either self reported positive test, or self-isolation of 7 or more days.
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in prevalence of anxiety from baseline
Time Frame: 4 months
|
Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. |
4 months
|
Change in prevalence of depression from baseline
Time Frame: 4 months followup
|
Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression |
4 months followup
|
Prevalence of sleep-related issues at baseline
Time Frame: At baseline
|
This is based on questions derived from the Insomnia Severity Index Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)
|
At baseline
|
Change in prevalence of sleep-related issues from baseline
Time Frame: 4-month follow-up
|
Insomnia Severity Index Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe) |
4-month follow-up
|
Prevalence of a combined outcome of presence of anyone of anxiety, depression or sleep related issues at baseline.
Time Frame: baseline
|
Symptoms of depression will be investigated using the 9- item Patient Health Questionnaire (PHQ-9). Min score of severity: 0-4 none, 20-27 severe. Higher score corresponding to more severe degree of depression Symptoms of anxiety will be investigated using the 7-item Generalised Anxiety Disorder (GAD- 7) Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher score corresponding to more severe degree of anxiety. Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe) |
baseline
|
Proportion of those with low mental wellbeing at baseline
Time Frame: baseline
|
This is based on questions derived from the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS).
Scores of 7-17 represent probable depression or anxiety; Scores of 18-20 suggest possible depression or anxiety.
|
baseline
|
Change in proportion of those with low mental wellbeing from baseline to the end of study.
Time Frame: 4-month follow-up
|
Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS).
Scores of 7-17 represent probable depression or anxiety; Scores of 18-20 suggest possible depression or anxiety
|
4-month follow-up
|
Prevalence of those who report concern related to work-place practices.
Time Frame: At baseline
|
Self-reported measures through responses to direct questions relevant to work-related practices in the survey
|
At baseline
|
Change in the prevalence from baseline of those who report concern related to work-place practices.
Time Frame: 6-week
|
Self-reported measures through responses to direct questions relevant to work-related practices in the survey
|
6-week
|
Change in the prevalence from baseline of those who report concern related to work-place practices.
Time Frame: 4 months
|
Self-reported measures through responses to direct questions relevant to work-related practices in the survey
|
4 months
|
Change in behavioural habits, such as smoking and alcohol intake from baseline to the end of study
Time Frame: 4-month follow-up
|
Self-reported measures through responses to survey questions
|
4-month follow-up
|
Proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19
Time Frame: Baseline
|
Self reported, based on the presence of symptoms with either self reported positive test, or self-isolation of 7 or more days.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ajay Gupta, MD, PhD, Queen Mary University London
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 284686
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Health
-
Chinese University of Hong KongNot yet recruitingMental Health Wellness 1 | Mental Well-being | Mental Health Issue | Precision Mental HealthHong Kong
-
King's College LondonCompletedMental Health Wellness 1 | Mental Health IssueUnited Kingdom
-
Chapin Hall at the University of ChicagoUniversity of ConnecticutCompletedMental Health | Physical Health
-
VA Office of Research and DevelopmentCompletedMental Health | Veterans Health | Rural HealthUnited States
-
National Taiwan Normal UniversityCompletedMental Health | Physical HealthTaiwan
-
Virginia Commonwealth UniversityCompletedMental Health DisordersUnited States
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMental Health DisordersCongo
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedMental Health DisordersNorway
-
University of WarwickKing's College London; KU Leuven; University Hospital, Montpellier; Erasmus Medical... and other collaboratorsUnknownMental Health Disorder | Mental Health ImpairmentIreland, United Kingdom, Netherlands, Germany, Belgium, Croatia, France, Italy
-
York UniversityCanadian Institutes of Health Research (CIHR); North York General HospitalCompletedMental Health DisordersCanada
Clinical Trials on Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...CompletedCOVID-19 | Infertility, Female | IVF | ARTItaly
-
Federico II UniversityCompletedCOVID | Psychological Distress | Severe Mental DisorderItaly
-
Zagazig UniversityUnknownHypertension With PregnancyEgypt
-
Kintsugi Mindful Wellness, Inc.CompletedHealthy | Mental Health Wellness 1 | Depression, AnxietyUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCanopy Cancer CollectiveActive, not recruitingPancreatic CancerUnited States
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedStress DisorderFrance, United Kingdom
-
General and Maternity Hospital of Athens Elena...National and Kapodistrian University of Athens; University of Ioannina; Larissa... and other collaboratorsCompletedPostpartum Depression | Psychological Stress | Maternal DistressGreece
-
University of IowaNot yet recruitingDelirium | Spinal Fusion | Pain, Back | Thoracolumbar Interfascial Plane BlockUnited States